Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease

Cancer Research

Volumn 62, Issue 13, 2002, Pages 3803-3811

  Zatyka, Malgorzata ^a   Da Silva, Nancy Fernandes ^a   Clifford, Steven C ^a   Morris, Mark R ^a   Wiesener, Michael S ^b   Eckardt, Kai Uwe ^b   Houlston, Richard S ^c   Richards, Frances M ^a   Latif, Farida ^a   Maher, Eamonn R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b HUMBOLDT UNIVERSITY   (Germany)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COLLAGEN TYPE 8; CYCLIN D1; INTEGRIN; INTERLEUKIN 6; MESSENGER RNA; PROTEIN; PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CARCINOGENESIS; CELL LINE; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

BLOTTING, NORTHERN; CARCINOMA, RENAL CELL; CYCLIN D1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; LIGASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXYGEN; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0036645091     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Identification of the von Hippel-Lindau disease tumor-suppressor gene
2. The VHL tumor-suppressor gene paradigm
3. Von Hippel-Lindau disease: Clinical and molecular perspectives
4. Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in nonfamilial clear cell renal carcinoma
5. Mutations of the VHL tumor-suppressor gene in renal-carcinoma
6. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal-carcinoma
7. Tumour suppression by the human von Hippel-lindau gene product
8. Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumorigenesis
9. Contrasting effects on HIF-iα regulation by disease-causing pVHL mutations correlate with patterns of tumorigenesis in von Hippel lindau disease
10. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: Evidence for modifier effects
11. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
12. Regulation of hypoxia inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2
13. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen dependent proteolysis
14. Hypoxia inducible factor-α binding and ubiquitilation by the von Hippel-Lindau tumor suppressor protein
15. Activation of H1F1 α ubiquitination by reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
16. Ubiquitination of hypoxia-inducible factor requires direct binding to the β domain of the von Hippel-Lindau protein
17. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
18. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix
19. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene
20. Hypoxia inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein
21. Transforming growth factor a is a target for the von Hippel-Lindau tumor suppressor
22. Alternate splicing produces a novel cyclin D1 transcript
23. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer
24. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age
25. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas
26. A Wilcoxon-type test for trend
27. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
28. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling
29. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene
30. Cyclin D1 expression in renal cell carcinomas and oncocytomas: An immunohistochemical study
31. Cyclin-D1 expression in human renal cell carcinoma
32. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization
33. Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
34. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1 α
35. Fibronectin, integrins and growth control
36. Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle
37. CD59 expressed on tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in rat model of human neuroblastoma
38. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones
39. Interleukin-6 family of cytokines and gp130
40. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma
41. Type VIII collagen is a product of vascular smooth-muscle cells in development and disease
42. Type VIII collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury
43. The Pezcoller Lecture. Cancer cell cycles revisited
44. 1 and is sufficient for cells arrested in G1 to complete the cell cycle
45. Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation
46. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck preliminary report
47. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival
48. Differential cyclin-dependent kinase expression and activation in human colon cancer
49. Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme
50. Candidate genes for the hypoxic tumor phenotype
51. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage
52. LuValle PTHrP control chondrocyte proliferation by activating cyclin D1 expression
53. The von Hippel-Lindau (VHL) tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C
54. The Von Hippel-Lindau protein interacts with hnRNP A2 and regulates its expression
55. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II
56. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: Evidence for a founder effect
57. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck
58. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation